EORTC-20981-LYMG

Intergroup Collaborative Study (EORTC 20981) "Rituximab (Mabthera*) in remission induction and maintenance treatment of relapsed / resistant follicular non-Hodgkin's lymphoma : a phase III randomized clinical trial" lymphoma : a phase III randomised clinical trial - Intergroup Collaborative Study (EORTC 20981) Including Amenmdment 4 (28.6.2000)
Study documentation
Trial StatusFurther follow-up after final analysis of primary endpoint
DatesDate of activation: 21-May-99
Date Step1 close: 26-Apr-04
Date Step2 close: 09-Dec-05
Data management at EORTCFull
Phase3
Randomized trialYes
TypeAdvanced
Targeted Sample size752
Number of steps2
Drug
Study Staff
Type of cancerNon Hodgkins Lymphoma
Participating GroupsEORTC Lymphoma Group(Coordinating Group)
Australasian Leukaemia and Lymphoma Group
British National Lymphoma Group
Hemato-Oncologie Volwassenen Nederland
NCIC Clinical Trial Group
Nordic Lymphoma Group
Schweizerisches Arbeitsgemeinschaft Klin. Krebsforschung
South African Non-Hodgkin Lymphoma Clinical Trials Group
Protocol summaryCancer.gov (PDQ)
ClinicalTrials.gov
NCT numberNCT00004179
EudraCT